Can-Fite BioPharma Appointed Dr. Ilan Cohn as Vice Chairman of the Board.PETACH TIKVA, Israel -- Can-Fite BioPharma (TASE TASE Tel Aviv Stock Exchange TASE The All Seeing Eye TASE Tactical Air Support Element TASE Thrust Assessment Support Environment TASE Telecontrol Application Service Elements (IEC communications protocol) :CFBI CFBI California Family Business Institute, LLC CFBI Center for Functional Brain Imaging ) announced today that Dr. Ilan Cohn, a member the of Board of Directors, was appointed by the Board of Directors as Vice Chairman of the Board. Dr. Ilan Cohn, who was the founder and seed investor in Can Fite BioPharma is a Senior Partner in Reinhold Cohn and Partners, Israel's largest intellectual property firm. Dr. Cohn is one of the leading patent attorneys in Israel, with particular expertise in the life sciences field. Dr. Cohn has a Ph.D. in biology from the Hebrew University of Jerusalem Hebrew University of Jerusalem Independent university in Jerusalem, Israel, founded in 1925. The foremost university in Israel, it attracts many Jewish students from abroad; Arab students also attend. . Throughout his professional career he gained extensive experience and expertise in business development in the biotechnology field and build-up of intellectual property platforms into key business assets. Dr. Cohn, through his global network, his extensive business development experience and his deep strategic intellectual property understanding, leads the company's business development. He was the architect and builder of the Company's intellectual property platform and managed to secure key patent licensing deals with the National Institute of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ) in the US and the Leiden University The Faculty of Creative and Performing Arts is a cooperation between Leiden University and the Royal Conservatoire and Royal Academy of Art. The university has never had a faculty of economics, business or management, since all these decades one thought this would not fit into its in the Netherlands, which led to the establishment of a multi-layered intellectual property platform that positions the company as a leader in the therapeutic field of drugs that target the A3 adenosine receptor Dr. Pnina Fishman, Can-Fite's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. said that "the appointment of Dr. Cohn as Vice Chairman was voted for unanimously by the Board of Directors and is in view of the Board's acknowledgement of his marked contribution to the company. I am very pleased with this nomination and I am confident that the company will continue to benefit from his talents and involvement in the company affairs". About Can-Fite Can-Fite BioPharma Ltd. is a public company, traded on the Tel-Aviv Stock Exchange that is headquartered in Petach-Tikva, Israel. The company, which began its operations at the end of 2000 was founded based on the work by Professor Pnina Fishman, formerly a Tumor Immunologist in the Rabin Medical Center The Rabin Medical Center is a medical center in Petah Tikva, Israel. It is currently the second largest medical center in Israel after Sheba Medical Center, having lost the title of largest in 2006. and currently the company's CEO, together with Dr Ilan Cohn, Patent Attorney and Senior Partner at Reinhold Cohn and Partners, a leading Israeli Patent Attorney firm. The Company has research laboratories and offices in Israel. The Company's lead drug, CF101, for the treatment of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. is currently in Phase II clinical trials and to date went through clinical trials in the USA, UK and Israel. About CF101 CF101 is a small molecule, which is administered to patients orally. This drug, which is developed for the treatment of rheumatoid arthritis, was tested to date in clinical trials in the USA, UK and Israel. The drug is active against a wide variety of autoimmune and cancer diseases and has a preferential safety profile. The drug's main advantage is in its ability to specifically attack pathological cells without affecting healthy ones. In addition, the fact that the drug is administered orally in the form of a capsule creates a huge advantage vs. current treatments which are administered by IV infusion or injection, at much higher costs. Rheumatoid arthritis (RA) is a severe and chronic autoimmune disease autoimmune disease, any of a number of abnormal conditions caused when the body produces antibodies to its own substances. In rheumatoid arthritis, a group of antibody molecules called collectively RF, or rheumatoid factor, is complexed to the individual's own gamma that affects more than 1% of the population in the Western World. The disease is characterized mainly by inflammation of the lining, or synovium, of the joints that can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. The market of disease modifying anti-rheumatic drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) A class of antirheumatic drugs, including chloroquine, methotrexate, cyclosporine, and gold compounds, that influence the disease process itself and do not only treat its symptoms. Mentioned in: Antirheumatic Drugs is estimated to be about US$ 5 billion and is expected to rise to about $7 billion by 2007. More information can be found at www.canfite.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion